Skip to main content
BrainCited

Citicoline ： Attention & Focus Difficulties

B

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
結論

            
            
Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                
                Double-blind
                
            

            
                Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.
            
            

                
                Dose: None
                
                
                vs: placebo
                
                
                Outcome: ADHD symptom improvement
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: pediatric patients aged 7-12 years diagnosed with ADHD

            
        

        
        

            

                
                    Other
                
                
                
                12 weeks
                
                
            

            
                Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.
            
            

                
                Dose: 19.17%
                
                
                vs: None
                
                
                Outcome: cognitive function
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: Covid-19 during the pandemic period between 2020 and 2022

            
        

        
        

            

                
                    Systematic Review
                
                
                n=8137
                
                
                
            

            
                Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: Cocaine craving reduction
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: Cocaine use disorder patients

            
        

        
        

            

                
                    Review
                
                
                
                
            

            
                Cholinergic nervous system and glaucoma: From basic science to clinical applications.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: Mortality
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: None

            
        

        
        

            

                
                    Review
                
                
                
                
            

            
                [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: None
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: None

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
14

        
研究数

    

    

        
1600

        
参加者数

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
グレード

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.
                        
                        
                            
                                RCT
                            
                            
                            
                        
                    

                    

                        Clinical neuropharmacology
                        None
                        
                        2 件の引用
                        
                    

                

                
                

                    

                        
                            Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Diagnostics (Basel, Switzerland)
                        2023
                        
                    

                

                
                

                    

                        
                            Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Brain sciences
                        2022
                        
                        17 件の引用
                        
                    

                

                
                

                    

                        
                            Cholinergic nervous system and glaucoma: From basic science to clinical applications.
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Progress in retinal …
                        2019
                        
                        107 件の引用
                        
                    

                

                
                

                    

                        
                            [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Revista de neurologia
                        2012
                        
                        12 件の引用
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
一般的な使用量

                

                    
                    

                        
general:

                        
250-500 mg/day

                    

                    
                    

                        
cognitivesupport:

                        
500-2,000 mg/day

                    

                    
                

                
                

                    上限量： Well-tolerated up to 4,000 mg/day in clinical trials
                

                
            

            

            
            

                
研究で検討された用量

                

                    

                        
                            

                                用量
                                期間
                                効果
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Neutral
                                    
                                
                                --
                            

                            
                            

                                19.17%
                                12 weeks
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                8137
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                推奨摂取タイミング： Morning or split dose; can be taken with or without food
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
報告されている副作用

                    
    
                        
                        
  • 
                            ⚠
                            Headache
                        
    • 
                        
                        
  • 
                            ⚠
                            Insomnia (if taken late in the day)
                        
    • 
                        
                        
  • 
                            ⚠
                            Mild gastrointestinal discomfort
                        
    • 
                        
                        
  • 
                            ⚠
                            Rare: restlessness or overstimulation
                        
    • 
                        
                    

                

                

                
                

                    
既知の相互作用

                    
    
                        
                        
  • 
                            ●
                            Levodopa (may enhance dopaminergic effects)
                        
    • 
                        
                        
  • 
                            ●
                            Cholinergic drugs (additive acetylcholine increase)
                        
    • 
                        
                        
  • 
                            ●
                            Anticholinergics (may reduce citicoline effectiveness)
                        
    • 
                        
                    

                

                

                
                

                    

                        耐容上限摂取量： Well-tolerated up to 4,000 mg/day in clinical trials
                    

                

                
            

            

                サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Citicoline help with Attention & Focus Difficulties?
            
        
        

            Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much Citicoline should I take for Attention & Focus Difficulties?
            
        
        

            Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Citicoline?
            
        
        

            Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Citicoline and Attention & Focus Difficulties?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                
                

                
                

                    
Citicoline 他の症状・状態について

                    

                        
                        
                            Memory Loss
                            B

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDAに関する免責事項:
        これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。